Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Parschauer Karah HerdmanEVP and Chief Legal Officer | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 06/15 | 06/15 | 1,899 sh | $24.62 | $46,753.38 | −2.0% |
Corazon D. SandersDirector | Ultragenyx PharmaceuticalRARE | Open-market sale | 06/15 | 06/15 | 2,000 sh | $25.05 | $50,100 | −8.7% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 06/01 | 06/01 | 4,653 sh | $23.77 | $110,601.81 | −4.2% |
Shehnaaz SulimanDirector | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 05/18 | 05/18 | 5,740 sh | $25.12 | $144,188.8 | −17.0% |
Eric CrombezEVP and Chief Medical Officer | Ultragenyx PharmaceuticalRARE | Open-market sale | 05/05 | 05/06 | 344 sh | $24.96 | $8,586.24 | −0.3% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 05/01 | 05/04 | 4,683 sh | $24.90 | $116,606.7 | −4.1% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 04/01 | 04/02 | 4,683 sh | $20.97 | $98,202.51 | −5.5% |
Ultragenyx PharmaceuticalRARE | Open-market sale | 03/06–03/10 | 03/10 | 9,526 sh2 trades | $21.87avg. | $208,311.56 | −12.5% | |
Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 03/02–03/03 | 03/03 | 10,044 sh3 trades | $22.65avg. | $227,538.26 | −10.6% | |
Kakkis Emil D.President & CEO | Ultragenyx PharmaceuticalRARE | Open-market sale | 03/02 | 03/03 | 54,404 sh | $22.80 | $1,240,411.2 | −7.6% |
Theodore Alan HuizengaSVP, Chief Accounting Officer | Ultragenyx PharmaceuticalRARE | Open-market sale | 03/02 | 03/03 | 1,632 sh | $22.80 | $37,209.6 | −3.2% |
John Richard PinionSEE REMARKS | Ultragenyx PharmaceuticalRARE | Open-market sale | 03/02 | 03/03 | 10,029 sh | $22.80 | $228,661.2 | −8.4% |
Eric CrombezEVP and Chief Medical Officer | Ultragenyx PharmaceuticalRARE | Open-market sale | 03/02 | 03/03 | 7,029 sh | $22.80 | $160,261.2 | −8.4% |
Parschauer Karah HerdmanEVP and Chief Legal Officer | Ultragenyx PharmaceuticalRARE | Open-market sale | 03/02 | 03/03 | 8,135 sh | $22.80 | $185,478 | −9.6% |
Erik HarrisEVP & Chief Commercial Officer | Ultragenyx PharmaceuticalRARE | Open-market sale | 03/02 | 03/03 | 10,539 sh | $22.80 | $240,289.2 | −10.5% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 02/02 | 02/03 | 3,061 sh | $23.56 | $72,117.16 | −3.3% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 01/02 | 01/05 | 3,150 sh | $22.84 | $71,946 | −3.3% |
Theodore Alan HuizengaSVP, Chief Accounting Officer | Ultragenyx PharmaceuticalRARE | Open-market sale | 25/12/29 | 25/12/30 | 85 sh | $34.38 | $2,922.3 | −0.2% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale10b5-1 plan | 25/12/10 | 25/12/11 | 3,081 sh | $36.38 | $112,086.78 | −3.1% |
Howard HornCFO | Ultragenyx PharmaceuticalRARE | Open-market sale | 25/10/13 | 25/10/14 | 7,942 sh | $31.51 | $250,252.42 | −7.5% |